Skip to main content

Table 3 Number (%) of adverse events and serious adverse in artemether-lumefantrine-treated subjects

From: A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso

  Adverse events up to day 7 Serious adverse events up to day 30
  AL-treated asymptomatic carriers AL-treated with symptomatic malaria episode with >5,000/μL parasites AL-treated asymptomatic carriers AL-treated with symptomatic malaria episode with >5,000/μL parasites
  (n = 3,819) (n = 2,554) (n = 3,819) (n = 2,554)
Abdominal pain 1 (0.03%) - 1 (0.03%) -
Nausea 1 (0.03%) - 1 (0.03%) -
Vomiting 1 (0.03%) 14 (0.5%) - 21 (0.8%)
Death 1 (0.03%) - 1 (0.03%) -
Pyrexia 1 (0.03%) - 1 (0.03%) -
Malaria 5 (0.1%) 2 (0.08%) 4 (0.1%) 5 (0.2%)
Bronchitis 2 (0.05%) - 2 (0.05%) -
Pneumonia 2 (0.05%) 1 (0.04%) 2 (0.05%) 2 (0.08%)
Respiratory tract infection 1 (0.03%) - 1 (0.03%) -
Dizziness 1 (0.03%) - 1 (0.03%) -
Asthmatic crisis 1 (0.03%) - - -
Somnolence - - - 1 (0.04%)